Author/Authors :
Xu, Xue Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Chen, Zhiyong Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Zhu, Xiaoxia Division of Rheumatology - Huashan Hospital - Fudan University -Shanghai 200040, China , Wang, Dandan Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Liang, Jun Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Zhao, Cheng Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Feng, Xuebing Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China , Wang, Jiucun State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology - School of Life Sciences - Fudan University - Shanghai 200433, China , Zou, Hejian Division of Rheumatology - Huashan Hospital - Fudan University - Shanghai 200040, China , Sun, Lingyun Department of Rheumatology and Immunology - Nanjing Drum Tower Hospital - the Affiliated Hospital of Nanjing University Medical School - Nanjing 210008 - Jiangsu, China
Abstract :
Objective(s):This study aims to investigate the pathogenicity and possible mechanisms of S100A9 function in mice models of scleroderma. Materials and Methods: The content of S100A9 in the skin tissues of mice with scleroderma was determined. Different concentrations of bleomycin (BLM) and S100A9 were subcutaneously injected into the backs of mice simultaneously, and then pathological changes in the skin of these mice were monitored. Specifically, the levels of inflammatory cytokines and alpha smooth muscle actin (α-SMA), the activation of extracellular regulated kinase 1/2 (ERK1/2), mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) pathways, and the expression of the receptor for advanced glycation end-product (RAGE) in the skin were determined. Results: The content of S100A9 in the skin tissues of mice with scleroderma was determined. Different concentrations of BLM and S100A9 were subcutaneously injected into the backs of mice simultaneously, and then pathological changes in the skin of these mice were monitored. Specifically, the levels of inflammatory cytokines and alpha smooth muscle actin (α-SMA), the activation of extracellular regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) pathways, and the expression of the receptor for advanced glycation end-product (RAGE) in the skin were determined.
Conclusion:S100A9 aggravates dermal fibrosis in BLM-induced scleroderma (BIS) mice, and its mechanisms might be mediated by RAGE, ERK1/2, and NF-κB pathway.
Keywords :
Bleomycin , ERK1/2 MAPK , NF-κB , RAGE , S100A9 , Scleroderma
